Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 782 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Retifanlimab February 26, 2024 Beloved Kindergarten Teacher Who Inspired Her Community Dies of Breast Cancer... April 8, 2021 Be a Holiday Helper! December 14, 2022 NCI Launches New Resource for Specimens and Data from Cancer Clinical... April 2, 2018 Load more HOT NEWS Mortality Trends for Most Cancers Remain Favourable In the EU, Although... TILs Therapy Shows Promise in the Management of Anti-PD-1-Resistant Metastatic NSCLC Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast
